Invirsa's lead therapeutic, INV-102, is a new treatment for ocular conditions that is derived from a naturally occurring small molecule which modulates the activity of pathways critical to the DNA damage repair response and cellular stability. The first pathway is the protein p53, known as 'the guardian of the genome,' and the second is Pax6 which is critical for cellular stability, particularly in the eye. In vitro tests have shown that INV-102 reduces cellular injury/death caused by adenovirus (the primary virus associated with infectious conjunctivitis) and other causes of DNA damage.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/14/23 | $7,700,000 | Series B |
CincyTech JobsOhio JumpStart Ventures Rev1 Ventures | undisclosed |
